Video
Expert insight on selection of androgen deprivation therapy and how related adverse events may be communicated to patients in advance.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
January 2023 AbbVie Inc. Company Confidential
Expert discusses the promise of emerging MISTs for BPH
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
2 Commerce Drive
Cranbury, NJ 08512